Back to search

Article

Mechanisms involved in cefiderocol resistance in French <i>Pseudomonas aeruginosa</i> clinical strains

2026-04-16

Abstract excerpt

Cefiderocol exhibits excellent in vitro activity against Pseudomonas aeruginosa ; however, resistance can emerge. We investigated the molecular mechanisms underlying cefiderocol resistance (MIC >2 mg/L) in 103 clinical strains collected from 61 hospitals (2021–2024). MICs ranged from 4 to >128 mg/L, with 39.8% of strains showing MICs >8 mg/L. Although 37.8% were classified as difficult-to-treat resistant (DTR),...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3d99647c-fb65-5f6c-b0b0-9fc7c1845e39
DOI
10.64898/2026.04.12.718081
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mechanisms involved in cefiderocol resistance in French <i>Pseudomonas aeruginosa</i> clinical strainsDOI 10.64898/2026.04.12.718081
Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program.Semantic proximity
Emergence of cefiderocol resistance mediated by blaAFM-1 overexpression and FptA mutations in clinical carbapenem-resistant Pseudomonas aeruginosa isolates.Semantic proximity
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosaSemantic proximity
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in <i>Pseudomonas aeruginosa</i> of clinical originSemantic proximity
In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.Semantic proximity
Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019–21Semantic proximity
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical TrialsSemantic proximity
In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.Semantic proximity
Molecular characteristics of chromosome-mediated colistin resistance in carbapenem-resistant Pseudomonas aeruginosa isolates from a tertiary hospital in China.Semantic proximity
Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosaSemantic proximity
Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing <em>Enterobacteriaceae</em>: Insights from Comparative GenomicsSemantic proximity
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin.Semantic proximity
Select a neighboring publication to make it the new centre.